Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 11, 2012

Primary Completion Date

September 29, 2016

Study Completion Date

September 29, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

DRUG

Dexamethasone

Trial Locations (11)

100081

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

200003

Shanghai Changzheng Hospital, Shanghai

200233

Shanghai 6th Hospital, Shanghai

215006

The 1st Hospital of Soochow University, Suzhou

300200

The 301 Hospital-Chinese PLA General Hospital, Beijing

310003

1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou

310009

1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou

410008

Xiangya Hospital of Central South University, Changsha

510080

Guangdong General Hospital, Guangzhou

510515

Nanfang Hospital of Southern medicine university in Guangzhou, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY